A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients.

"Declarations Conflict of interestStephen Freedland has had consulting or advisory roles for Astellas Pharma, AstraZeneca, Janssen Biotech, Bayer, Pfizer, Sanofi, Myovant Sciences, Merck, and Exact Sciences; has received compensation for travel from Sanofi; and has had speakers bureau role for Sanofi and AstraZeneca. Sandhya Nair has employment from Janssen Research & Development. Xiwu Lin has employment from Janssen Research & Development, and has stock and ownership interests in Johnson & Johnson. Lawrence Karsh has had consulting or advisory roles for Astellas, AstraZeneca, Bayer, Dendreon, Ferring, Janssen, Merck, Pfizer, Sanofi and Daiichi-Sankyo; has had speakers bureau roles for Astellas, AstraZeneca, Bayer, Dendreon, Janssen, Merck, Myovant, and Pfizer; has stock and ownership interests in Swan Valley Medical; and receives research funding to his institution from Astellas, Bayer, Bristol Myers Squibb, Dendreon, FKD, Janssen, KDx, Myovant, Oncocell, Pfizer, and Tavanta. Christopher Pieczonka has employment from Associated Medical Professionals of New York; has had consulting or advisory roles for Pfizer/Astellas, Bayer, Janssen Oncology, Tolmar, Sun Pharma, Dendreon, AstraZeneca, Merck, and Bristol Myers Squibb; has a leadership role for Associated Medical Professionals of New York; has had speakers bureau roles for Bayer, Dendreon, Pfizer, Astellas Pharma, Sun Pharma, Myovant Sciences, Janssen Oncology, and Foundation Medicine; has stock and ownership interests in US Urology Partners; has received honoraria from Janssen, Dendreon, Pfizer, Astellas, Bayer, Sun Pharma, Myovant Sciences, Merck, AstraZeneca, and Bristol Myers Squibb; and has received research funding from Bayer, Pfizer, Astellas Pharma, Merck, AstraZeneca, Advantagene, Dendreon, and Janssen Oncology. Ravi Potluri reports institutional consulting fees received by his employer Putnam Associates. Sabine D. Brookman-May has employment from Janssen Research & Development; has a leadership role at Janssen Research & Development; has stock and ownership interests in Johnson & Johnson; and has a consulting role for Wellster Healthtech. Suneel Mundle has employment from Janssen Research & Development. Neeraj Agarwal has received consulting fees from Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics over his lifetime; and his institution has received payment (for clinical trials) from Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. Sarah Fleming has employment from Janssen Research & Development; and has stock and ownership interests in Johnson & Johnson. Ethical approvalAs this is a retrospective database study, no ethics approval is required. Conflict of interest Stephen Freedland has had consulting or advisory roles for Astellas Pharma, AstraZeneca, Janssen Biotech, Bayer, Pfizer, Sanofi, Myovant Sciences, Merck, and Exact Sciences; has received compensation for travel from Sanofi; and has had speakers bureau role for Sanofi and AstraZeneca. Sandhya Nair has employment from Janssen Research & Development. Xiwu Lin has employment from Janssen Research & Development, and has stock and ownership interests in Johnson & Johnson. Lawrence Karsh has had consulting or advisory roles for Astellas, AstraZeneca, Bayer, Dendreon, Ferring, Janssen, Merck, Pfizer, Sanofi and Daiichi-Sankyo; has had speakers bureau roles for Astellas, AstraZeneca, Bayer, Dendreon, Janssen, Merck, Myovant, and Pfizer; has stock and ownership interests in Swan Valley Medical; and receives research funding to his institution from Astellas, Bayer, Bristol Myers Squibb, Dendreon, FKD, Janssen, KDx, Myovant, Oncocell, Pfizer, and Tavanta. Christopher Pieczonka has employment from Associated Medical Professionals of New York; has had consulting or advisory roles for Pfizer/Astellas, Bayer, Janssen Oncology, Tolmar, Sun Pharma, Dendreon, AstraZeneca, Merck, and Bristol Myers Squibb; has a leadership role for Associated Medical Professionals of New York; has had speakers bureau roles for Bayer, Dendreon, Pfizer, Astellas Pharma, Sun Pharma, Myovant Sciences, Janssen Oncology, and Foundation Medicine; has stock and ownership interests in US Urology Partners; has received honoraria from Janssen, Dendreon, Pfizer, Astellas, Bayer, Sun Pharma, Myovant Sciences, Merck, AstraZeneca, and Bristol Myers Squibb; and has received research funding from Bayer, Pfizer, Astellas Pharma, Merck, AstraZeneca, Advantagene, Dendreon, and Janssen Oncology. Ravi Potluri reports institutional consulting fees received by his employer Putnam Associates. Sabine D. Brookman-May has employment from Janssen Research & Development; has a leadership role at Janssen Research & Development; has stock and ownership interests in Johnson & Johnson; and has a consulting role for Wellster Healthtech. Suneel Mundle has employment from Janssen Research & Development. Neeraj Agarwal has received consulting fees from Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics over his lifetime; and his institution has received payment (for clinical trials) from Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. Sarah Fleming has employment from Janssen Research & Development; and has stock and ownership interests in Johnson & Johnson."

"Funding Open access funding provided by SCELC, Statewide California Electronic Library Consortium."